Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.8K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.8K
Seizures l: Introduction01:20

Seizures l: Introduction

43
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
43
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Epilepsy ll: Types01:22

Epilepsy ll: Types

73
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
73

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A first in disease trial of the safety, tolerability, and anti-seizure effects of ES-481 in drug-resistant epilepsy.

Epilepsia open·2026
Same author

Response to "Between pregnancies: An educational window in women with epilepsy".

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Neurocognitive Outcomes of In Utero Exposure to Antiseizure Medication: An Australian Cohort Study.

Neurology·2026
Same author

On-site exposure to clinical epilepsy practice for experimental scientists engaged in epilepsy research: A pilot study by the ILAE commission on neurobiology.

Epilepsia open·2026
Same author

Elevated ADHD symptoms linked to depression and anxiety in women with epilepsy.

Epilepsy & behavior : E&B·2026
Same author

Feasibility and signal quality of the Minder® implantable continuous EEG monitoring® system compared to 10-20 scalp electrodes over extended monitoring periods.

Epilepsia·2026

Related Experiment Video

Updated: May 7, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.1K

Untreated epilepsy and pregnancy.

Frank J E Vajda1, Terence J O'Brien2, Janet E Graham3

  • 1Departments of Medicine and Neurosciences, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria 3050, Australia; Department of Neuroscience, The School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.

Seizure
|May 5, 2026
PubMed
Summary
This summary is machine-generated.

Untreated pregnant women with epilepsy (WWE) had fewer fetal malformations (FM) compared to those on antiseizure medication (ASM). Seizure freedom rates were similar between treated and untreated groups, suggesting careful consideration of ASM therapy during pregnancy.

Keywords:
Pre-pregnancy year important factorReduced malformationsSeizure rate not significantly higherUntreated WWE

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

19.1K

Related Experiment Videos

Last Updated: May 7, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.1K
Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

19.1K

Area of Science:

  • Neurology
  • Obstetrics
  • Teratology

Background:

  • Epilepsy in pregnancy poses risks to both mother and fetus.
  • Antiseizure medications (ASMs) are crucial for seizure control but may carry teratogenic risks.
  • Data on untreated pregnant women with epilepsy (WWE) is scarce.

Purpose of the Study:

  • To evaluate the risk of fetal malformation (FM) in untreated pregnant WWE.
  • To assess seizure freedom maintenance in untreated pregnant WWE.
  • To compare outcomes between treated and untreated pregnancies using Australian Pregnancy Register (APR) data.

Main Methods:

  • Analysis of 2826 pregnancies in the APR (1999-2025).
  • Comparison of FM rates between 128 continuously untreated pregnancies and 2538 continuously ASM-treated pregnancies.
  • Assessment of seizure freedom rates in both groups.

Main Results:

  • A trend towards lower FM occurrence in untreated pregnancies (RR=0.48, 95% CI 0.23-1.00).
  • No statistically significant difference in seizure freedom rates between untreated and ASM-treated groups (RR=0.90, 95% CI 0.82-1.08).
  • Seizures during pregnancy influenced the decision to restart ASM therapy.

Conclusions:

  • While not statistically significant due to small numbers, a lower incidence of FM was observed in untreated pregnancies.
  • ASM therapy status did not significantly impact seizure freedom rates.
  • Findings suggest careful management decisions regarding ASM use in pregnant WWE, considering seizure control and potential teratogenicity.